120 related articles for article (PubMed ID: 24388104)
1. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Elsberger B
Crit Rev Oncol Hematol; 2014 Mar; 89(3):343-51. PubMed ID: 24388104
[TBL] [Abstract][Full Text] [Related]
2. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
3. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
[TBL] [Abstract][Full Text] [Related]
4. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
5. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
8. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
9. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
Chu I; Arnaout A; Loiseau S; Sun J; Seth A; McMahon C; Chun K; Hennessy B; Mills GB; Nawaz Z; Slingerland JM
J Clin Invest; 2007 Aug; 117(8):2205-15. PubMed ID: 17627304
[TBL] [Abstract][Full Text] [Related]
10. Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.
Cho NL; Lin CI; Du J; Whang EE; Ito H; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2012 May; 421(3):508-13. PubMed ID: 22521882
[TBL] [Abstract][Full Text] [Related]
11. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
12. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.
Payne SL; Fogelgren B; Hess AR; Seftor EA; Wiley EL; Fong SF; Csiszar K; Hendrix MJ; Kirschmann DA
Cancer Res; 2005 Dec; 65(24):11429-36. PubMed ID: 16357151
[TBL] [Abstract][Full Text] [Related]
13. RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Oncol Rep; 2011 Nov; 26(5):1243-50. PubMed ID: 21725611
[TBL] [Abstract][Full Text] [Related]
14. Targeting Src in breast cancer.
Finn RS
Ann Oncol; 2008 Aug; 19(8):1379-1386. PubMed ID: 18487549
[TBL] [Abstract][Full Text] [Related]
15. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
17. The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
Goel RK; Miah S; Black K; Kalra N; Dai C; Lukong KE
FEBS J; 2013 Sep; 280(18):4539-59. PubMed ID: 23822091
[TBL] [Abstract][Full Text] [Related]
18. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells.
Sigstedt SC; Hooten CJ; Callewaert MC; Jenkins AR; Romero AE; Pullin MJ; Kornienko A; Lowrey TK; Slambrouck SV; Steelant WF
Int J Oncol; 2008 May; 32(5):1085-90. PubMed ID: 18425335
[TBL] [Abstract][Full Text] [Related]
20. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
